Webinar
24 Jan 2023

Container Closure Integrity (CCI) Testing

In this webinar, originally broadcast as part of the Pharmapack Europe show, Robert Schultheis, Founder & Chief Technology Officer, ZebraSci discusses:

  • Probabilistic vs deterministic CCI Testing
  • Presentation of the different deterministic CCI testing methods with applications and limitations
  • What to consider when selecting CCI testing method
  • In this session the audience will benefit from understanding the influence of the drug specificities to select the most suitable technical option for Container Closure Integrity testing activities
  • based on the advantages and limitations of different techniques available on the market

    Content provided by our supplier

    ZebraSci Inc.

    • US
    • 2022
      On CPHI since
    • 1
      Certificates
    • 1 - 24
      Employees
    Company types
    Contract Service
    Primary activities
    Laboratory Services

    Other Content from ZebraSci Inc. (2)

    • Brochure Supporting your combination product development from concept to market

      Streamlined Solutions. Dependable Service. Technical Expertise.
    • Webinar Challenges of Extractables & Leachables Experience

      The investigation of the chemical compatibility between a drug product and its container relates to drug product quality, efficacy and safety - critical parameters for the development and commercialisation of a drug product. This implies assessing the extractables and leachables for each new drug product before submission for marketing authorization, and to re-evaluate requirements for each variation of an existing drug product. A 'Toxicological Risk Assessment' must also be conducted to evaluate patient exposure to chemicals over shelf-life and it is the responsibility of a Pharmaceutical company to provide timely evidence on the quality of their finished product. Tools & methodology for E&L studies can be deployed to anticipate challenges and provide key data to de-risk your drug combination product development, even at an early stage.